Search

Your search keyword '"Takkenberg, Bart"' showing total 34 results
Start Over Author "Takkenberg, Bart"
34 results on '"Takkenberg, Bart"'

1. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe

Author

Patmore, Lesley A., van Eekhout, Kirsi M.A., Buti, Maria, Koc, Özgur.M., Agarwal, Kosh, de Knegt, Rob J., Janssen, Harry L.A., van der Valk, Marc, Lieveld, Faydra I., Hansen, Bettina E., Kramer, Matthijs, de Bruijne, Joep, Claassen, Mark A.A., Smit, Colette, de Man, Rob A., Takkenberg, Bart, Carey, Ivana, and Sonneveld, Milan J.

Published
2024
Full Text
View/download PDF

3. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe

Author

UMC Utrecht Holding, Unit Opleiding Aios, MS MDL 1, Patmore, Lesley A., van Eekhout, Kirsi M.A., Buti, Maria, Koc, Özgur M., Agarwal, Kosh, de Knegt, Rob J., Janssen, Harry L.A., van der Valk, Marc, Lieveld, Faydra I., Hansen, Bettina E., Kramer, Matthijs, de Bruijne, Joep, Claassen, Mark A.A., Smit, Colette, de Man, Rob A., Takkenberg, Bart, Carey, Ivana, Sonneveld, Milan J., the HARP study group and HepNed, UMC Utrecht Holding, Unit Opleiding Aios, MS MDL 1, Patmore, Lesley A., van Eekhout, Kirsi M.A., Buti, Maria, Koc, Özgur M., Agarwal, Kosh, de Knegt, Rob J., Janssen, Harry L.A., van der Valk, Marc, Lieveld, Faydra I., Hansen, Bettina E., Kramer, Matthijs, de Bruijne, Joep, Claassen, Mark A.A., Smit, Colette, de Man, Rob A., Takkenberg, Bart, Carey, Ivana, Sonneveld, Milan J., and the HARP study group and HepNed

Published
2024

7. Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Author

Wieske, Luuk, primary, Stalman, Eileen W, additional, van Dam, P J Koos, additional, Kummer, Laura Y, additional, Steenhuis, Maurice, additional, van Kempen, Zoe L E, additional, Killestein, Joep, additional, Volkers, Adriaan G, additional, Tas, Sander W, additional, Boekel, Laura, additional, Wolbink, Gertjan, additional, Van der Kooi, Anneke, additional, Raaphorst, Joost, additional, Löwenberg, Mark, additional, Takkenberg, Bart, additional, D’Haens, Geert R A M, additional, Spuls, Phyllis I, additional, Bekkenk, Marcel W, additional, Musters, Annelie H, additional, Post, Nicoline F, additional, Bosma, Angela L, additional, Hilhorst, Marc L, additional, Vegting, Yosta, additional, Bemelman, Frederique J, additional, Voskuyl, Alexandre, additional, Broens, Bo, additional, Parra Sanchez, Agner, additional, van Els, Cécile A C M, additional, Wit, Jelle De, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horváth, Barbara, additional, Verschuuren, Jan J G M, additional, Ruiter, Annabel M, additional, van Ouwerkerk, Lotte, additional, van der Woude, Diane, additional, Allaart, Cornelia F, additional, Teng, Y K Onno, additional, van Paassen, Pieter, additional, Busch, Matthias H, additional, Jallah, Papay B P, additional, Brusse, Esther, additional, van Doorn, Pieter A, additional, Baars, Adája Elisabeth, additional, Hijnen, Dirkjan, additional, Schreurs, Corine R G, additional, Van der Pol, W Ludo, additional, Goedee, H Stephan, additional, Keijzer, Sofie, additional, Keijser, Jim, additional, Cristianawati, Olvi, additional, ten Brinke, Anja, additional, Verstegen, Niels J M, additional, Zwinderman, Koos A H, additional, van Ham, S Marieke, additional, Kuijpers, Taco W, additional, Rispens, Theo, additional, and Eftimov, Filip, additional

Published
2023
Full Text
View/download PDF

8. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

Author

Dam, Koos van, primary, Volkers, Adriaan, additional, Wieske, Luuk, additional, Stalman, Eileen, additional, Kummer, Laura, additional, kempen, Zoe van, additional, Killestein, Joep, additional, Tas, Sander, additional, Boekel, Laura, additional, Wolbink, Gertjan, additional, Kooi, Anneke van der, additional, Raaphorst, Joost, additional, Takkenberg, Bart, additional, D'Haens, Geert, additional, Spuls, Phyllis, additional, Bekkenk, Marcel, additional, Musters, Annelie, additional, Post, Nicoline, additional, Bosma, Angela, additional, Hilhorst, Marc, additional, Vegting, Yosta, additional, Bemelman, Frederike, additional, Voskuyl, Alexandre, additional, Broens, Bo, additional, Sanchez, Agner Parra, additional, Els, Cecile van, additional, de Wit, Jelle, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horvath, Barbara, additional, Verschuuren, Jan, additional, Ruiter, Annabel, additional, Ouwerkerk, Lotte van, additional, Woude, Diane van der, additional, Allaart, Renee, additional, Teng, Onno, additional, Paassen, Pieter van, additional, Busch, Matthias, additional, Jallah, Papay, additional, Brusse, Esther, additional, Doorn, Pieter van, additional, Baars, Adaja, additional, Hijnen, DirkJan, additional, Schreurs, Corine, additional, Pol, Ludo van der, additional, Goedee, Stephan, additional, Steenhuis, Maurice, additional, Keijzer, Sofie, additional, Keijser, Jim, additional, Cristianawati, Olvi, additional, Brinke, Anja ten, additional, Verstegen, Niels, additional, Ham, Marieke van, additional, Rispens, Theo, additional, Kuijpers, Taco, additional, Lowenberg, Mark, additional, and Eftimov, Filip, additional

Published
2023
Full Text
View/download PDF

10. Functional assessment of liver regeneration after major hepatectomy

Author

Rassam, Fadi, primary, Olthof, Pim B., additional, Takkenberg, Bart, additional, Besselink, Marc G., additional, Busch, Olivier R., additional, Erdmann, Joris I., additional, Swijnenburg, Rutger-Jan, additional, van Lienden, Krijn P., additional, Beuers, Ulrich H., additional, Bennink, Roelof J., additional, and van Gulik, Thomas M., additional

Published
2022
Full Text
View/download PDF

22. Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma

Author

Vries, Elsemieke, primary, Mazzetti, Marta, additional, Takkenberg, Bart, additional, Mostafavi, Nahid, additional, Bikker, Hennie, additional, Marzioni, Marco, additional, Veer, Rozanne, additional, Meer, Adriaan, additional, Doukas, Michael, additional, Verheij, Joanne, additional, and Beuers, Ulrich, additional

Published
2020
Full Text
View/download PDF

24. Heterozygous carriers of ABCB4 mutations show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma – a cohort study

Author

Mazzetti, Marta, primary, de Vries, Elsemieke, additional, Takkenberg, Bart, additional, Mostafavi, Nahid, additional, Bikker, Henny, additional, Marzioni, Marco, additional, de Veer, Rozanne, additional, Van der Meer, Adriaan, additional, Doukas, Michael, additional, Verheij, Joanne, additional, and Beuers, Ulrich, additional

Published
2020
Full Text
View/download PDF

27. Sorafenib for Patients with Hepatocellular Carcinoma and Child‐Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study.

Author

Labeur, Tim A., Achterbergh, Roos, Takkenberg, Bart, Van Delden, Otto, Mathôt, Ron, and Klümpen, Heinz‐Josef

Subjects
CLINICAL trials, DRUG efficacy, DRUG toxicity, HEPATOCELLULAR carcinoma, CIRRHOSIS of the liver, SURVIVAL, TREATMENT effectiveness, SEVERITY of illness index, DESCRIPTIVE statistics, SORAFENIB, EVALUATION
Abstract

Lessons Learned: Recruitment of patients with advanced hepatocellular carcinoma and Child‐Pugh B for sorafenib treatment and additional pharmacokinetic studies is challenging.Patients with Child‐Pugh B liver cirrhosis have high rates of cirrhosis‐related adverse events. Background: Few data are available on the pharmacokinetics (PK) of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child‐Pugh B liver cirrhosis. This study aimed to explore the sorafenib PK and its relationship with efficacy and toxicity in these patients. Methods: Patients with advanced HCC and Child‐Pugh B7‐8 liver function were prospectively recruited at a tertiary center. Adverse events (AEs), progression‐free survival (PFS), and overall survival (OS) were recorded. Patients received a starting dose of 200 b.i.d. with toxicity‐adjusted dose escalation to a target dose of 400 mg b.i.d. with PK sampling at fixed time points. Results: Between May 2014 and March 2017, 12 patients were screened, of whom 7 progressed to a terminal stage during the screening (n = 6) or shortly after recruitment (n = 1). The five included patients had median PFS of 3.8 months (range, 1.7–10.8) and OS of 7.4 months (range, 1.7–25.8). Three patients had severe AEs and one patient had a partial response with an OS of 25.8 months. In 2017, the trial was aborted for lack of accrual. Conclusion: Because of low accrual, no conclusion can be drawn on the sorafenib PK in patients with advanced HCC and Child‐Pugh B liver cirrhosis. The poor survival and frequent cirrhosis‐related AEs suggest limited benefit for most of these patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

30. PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma

Author

Sideras, Kostandinos, primary, Biermann, Katharina, additional, Verheij, Joanne, additional, Takkenberg, Bart R., additional, Mancham, Shanta, additional, Hansen, Bettina E., additional, Schutz, Hannah M., additional, de Man, Robert A., additional, Sprengers, Dave, additional, Buschow, Sonja I., additional, Verseput, Maddy C. M., additional, Boor, Patrick P. C., additional, Pan, Qiuwei, additional, van Gulik, Thomas M., additional, Terkivatan, Turkan, additional, Ijzermans, Jan N. M., additional, Beuers, Ulrich H. W., additional, Sleijfer, Stefan, additional, Bruno, Marco J., additional, and Kwekkeboom, Jaap, additional

Published
2017
Full Text
View/download PDF

32. Experimental Hbsag/Anti-Hbs Complex Assay for Prediction of Hbeag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon and Adefovir

Author

de Niet, Annikki, Jansen, Louis, Zaaijer, Hans L, Klause, Ursula, Takkenberg, Bart, Janssen, Harry LA, Chu, Tom, Petric, Rosemary, and Reesink, Hendrik W

Abstract

Background We studied whether hepatitis B surface antigen (HBsAg)/anti-HBs immune complex levels in chronic hepatitis B (CHB) patients receiving antiviral therapy could be used as a response marker at baseline (BL) or early during treatment to predict treatment outcome.Methods An experimental array-based assay (immunological multi-parameter chip technology [IMPACT]; Roche Diagnostics, Penzberg, Germany) served to determine HBsAg, anti-HBs and complex levels. We tested a panel of serum samples of 40 hepatitis B e antigen (HBeAg)-positive and 44 HBeAg-negative patients who received pegylated interferon and adefovir for 48 weeks.Results HBsAg loss occurred in 4 of 40 HBeAg-positive and 4 of 44 HBeAg-negative patients. A total of 14 of 40 HBeAg-positive patients lost HBeAg and 12 of them formed anti-HBe. At BL, complexes were present in 83 (99%) patients, whereas free anti-HBs levels were detectable in 5 patients. Complex levels at BL and week 12 were higher in HBeAg-positive patients with HBeAg loss, compared to patients who retained HBeAg (P=0.002 and P=0.005, respectively). Receiver operating characteristic analysis for HBeAg loss in HBeAg-positive patients at BL and week 12 showed area-under-the-curve values of 0.79 (P=0.002) and 0.82 (P=0.003) for complex levels. We found no correlation in either HBeAg-positive or -negative patients between complex levels and HBsAg loss.Conclusions We demonstrated for the first time that before and during treatment HBsAg/anti-HBs immune complex levels can predict HBeAg loss in HBeAg-positive CHB patients treated with pegylated interferon and adefovir. Complexes were present in almost all patients at BL and were higher in patients who lost HBeAg. In conclusion, determining HBsAg/anti-HBs immune complex levels before and early during treatment could aid in selecting CHB patients with an optimal chance to achieve HBeAg loss.

Published
2014
Full Text
View/download PDF

33. PD-L1, Galectin-9 and CD8+tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma

Author

Sideras, Kostandinos, Biermann, Katharina, Verheij, Joanne, Takkenberg, Bart R., Mancham, Shanta, Hansen, Bettina E., Schutz, Hannah M., de Man, Robert A., Sprengers, Dave, Buschow, Sonja I., Verseput, Maddy C. M., Boor, Patrick P. C., Pan, Qiuwei, van Gulik, Thomas M., Terkivatan, Turkan, Ijzermans, Jan N. M., Beuers, Ulrich H. W., Sleijfer, Stefan, Bruno, Marco J., and Kwekkeboom, Jaap

Abstract

ABSTRACTNovel systemic treatments for hepatocellular carcinoma (HCC) are strongly needed. Immunotherapy is a promising strategy that can induce specific antitumor immune responses. Understanding the mechanisms of immune resistance by HCC is crucial for development of suitable immunotherapeutics. We used immunohistochemistry on tissue-microarrays to examine the co-expression of the immune inhibiting molecules PD-L1, Galectin-9, HVEM and IDO, as well as tumor CD8+lymphocyte infiltration in HCC, in two independent cohorts of patients. We found that at least some expression in tumor cells was seen in 97% of cases for HVEM, 83% for PD-L1, 79% for Gal-9 and 66% for IDO. In the discovery cohort (n = 94), we found that lack of, or low, tumor expression of PD-L1 (p< 0.001), Galectin-9 (p< 0.001) and HVEM (p< 0.001), and low CD8+TIL count (p= 0.016), were associated with poor HCC-specific survival. PD-L1, Galectin-9 and CD8+TIL count were predictive of HCC-specific survival independent of baseline clinicopathologic characteristics and the combination of these markers was a powerful predictor of HCC-specific survival (HR 0.29; p<0.001). These results were confirmed in the validation cohort (n = 60). We show that low expression levels of PD-L1 and Gal-9 in combination with low CD8+TIL count predict extremely poor HCC-specific survival and it requires a change in two of these parameters to significantly improve prognosis. In conclusion, intra-tumoral expression of these immune inhibiting molecules was observed in the majority of HCC patients. Low expression of PD-L1 and Galectin-9 and low CD8+TIL count are associated with poor HCC-specific survival. Combining immune biomarkers leads to superior predictors of HCC mortality.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results